BBP

Virtus LifeSci Biotech Products ETF
N/A

N/A
*Unless otherwise stated, data provided by FactSet.

BBP Fund Description

The Virtus LifeSci Biotech Products ETF tracks an index of biotechnology companies considered to be in the "product stage" by the index provider.

BBP Factset Analytics Insight

BBP offers a different approach to biotech investing by handpicking only firms that have attained FDA approval for their leading drug. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. BBP is likely to tilt smaller than our neutral cap-weighted benchmark because the fund equal-weights its holdings, and it dips into micro-caps as well. Unsurprisingly, risk is elevated compared to our benchmark. BBP can be tricky to trade at any scale. Onscreen volume is thin and spreads are large, while the small-cap basket may cause some liquidity problems for larger investors. It also charges a very high expense ratio for this segment. Overall, BBP provides an alternative but pricey take on the biotech segment.

BBP MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of June 19, 2018 the Virtus LifeSci Biotech Products ETF MSCI ESG Fund Quality Score is 4.01 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. BBP ranks in the 10th percentile within its peer group and in the 9th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

BBP CHARTS AND PERFORMANCE

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:
PERFORMANCE [as of 06/19/18] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
BBP 4.56% 7.91% 11.34% 17.66% 8.69% -- --
BBP (NAV) 4.63% 6.86% 11.66% 17.42% 8.86% -- --
Thomson Reuters US Biotechnology & Medical Research 3.70% -3.21% 6.64% 19.42% 0.08% 17.56% --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

BBP Top 10 Countries

BBP Top 10 Sectors

BBP Top 10 Holdings [View All]

BBP Summary Data

Virtus
12/17/14
Open-Ended Fund
0.79%
$33.20M
$212.33K
0.28%

BBP Portfolio Data

$13.64B
-15.70
6.72
0.16%
N/A
38

BBP Index Data

Equal
Proprietary
Thomson Reuters US Biotechnology & Medical Research

BBP Portfolio Management

0.79%
--
--
--

BBP Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

BBP Fund Structure

Open-Ended Fund
No
Yes
No Policy
N/A
N/A
High
Daily
Bats Book Viewer
TOP OF BOOK
LAST 10 TRADES
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

BBP Factset Analytics Block Liquidity

As of 06/20/18
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BBP. BBP is rated a 4 out of 5.

BBP Tradability

4,927
$212.33K
1,338
$57.16K
0.28%
$0.12
-0.03%
2.41% / -2.37%
None
100.00%
50,000
0.03
0.02%
0.32%
--
$45.22
4

BBP Sector/Industry Breakdown


BBP
Segment Benchmark
87.31%
87.58%
12.69%
--

BBP TOP 10 HOLDINGS[View All]

4.78%
4.44%
4.33%
3.96%
3.59%
3.49%
3.43%
3.24%
3.22%
3.18%
37.66%

BBP Countries


BBP
Segment Benchmark
100.00%
100.00%

BBP Regions


BBP
Segment Benchmark
100.00%
100.00%

BBP Economic Development


BBP
Segment Benchmark
100.00%
100.00%

BBP Performance Statistics

0.83
1.01
1.03
0.89
0.64%
Thomson Reuters US Biotechnology & Medical Research

BBP MSCI ESG Ratings

4.01 / 10
9.50
9.19
--
14.93%
24.31

BBP BENCHMARK COMPARISON HOLDINGS

38
145
31
26.18%

BBP BENCHMARK COMPARISON SUMMARY


BBP
Segment Benchmark
38
145
$13.64B
$31.38B
-15.70
-46.83
6.72
5.69
0.15%
0.72%
--
--

BBP BENCHMARK COMPARISON MARKET CAP SIZE


BBP
Segment Benchmark
23.22%
44.64%
29.39%
31.22%
44.76%
20.52%
2.63%
3.63%

Options Strategies for Outcome Investing

A collar strategy is a protective option strategy constructed by writing a call and buying a put with the same expiration date while being long the underlying security.